Licun Wu, MD
Researcher, Latner Thoracic Surgery Research Laboratories and Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, M5G 1L7, Canada
Dr. Wu is working in Toronto General Hospital as a research scientist and also a professor of Experimental Oncology in Shandong Academy of Medical Sciences, Jinan, China. He has been working on experimental oncology since graduating from Shandong Medical University, China in 1980s. He got training as a postdoctoral fellow in Princess Margaret Hospital/Ontario Cancer Institute, University of Toronto, Canada. Then he completed 2-year fellowship at Baylor Institute for Immunology Research (BIIR), Dallas, Texas.
Dr. Wu joined Toronto Mesothelioma Research Program led by the internationally recognized expert Dr. Marc de Perrot. His team are focusing on experimental therapeutics of cancers especially malignant pleural mesothelioma (MPM). MPM is a rarely found cancer in the general population, but it is rather common among construction and industry workers who have been exposed to asbestos. MPM originates from the lining of the pleura, and is usually misdiagnosed until its advanced stage, therefore, the efficacy of current treatment options are very limited. The overall goal of his study is to improve the efficacy of mesothelioma treatment by immune modulation either through activating T cell response or removing the immune “brakes” (Treg cells, immune checkpoints, etc.) to allow the immune system to kill the surviving cancer cells after treatment with surgery, radiotherapy, or chemotherapy. He has demonstrated that blockade of the immune suppressive signals similarly as release of the brake in combination with conventional therapies to treat mesothelioma can induce specific immunity against tumor.He has published several impact papers, and he is an active member of several professional and scientific societies including the American Association for Cancer Research (AACR), International Association for the Study of Lung Cancer (IASLC), International Mesothelioma Interest Group (IMIG), and Canadian Cancer Immunotherapy Consortium (CCIC).